Around 4,000 men newly diagnosed with high-risk metastatic hormone-sensitive prostate cancer would have been eligible for treatment with the drug
Around 4,000 men newly diagnosed with high-risk metastatic hormone-sensitive prostate cancer would have been eligible for treatment with the drug
The £3.2-million study will investigate whether there are any genetic causes of ME
NICE says the cost-effectiveness of the drug is uncertain, but Novartis says the decision denies patients access to the first licensed oral therapy for SPMS with active disease
The drug is the first to be recommended as a treatment for the virus in the EU
The triple therapy is currently under review for COPD in both the EU and US
The move provides the opportunity to conduct essential post-marketing surveillance
The trial will see around 300 people given the vaccine plus a booster shot up to four weeks after the first dose
The ‘landmark’ decision invalidates Regeneron’s patent claims covering its genetically modified mice
The drug targets all solid tumours with the NTRK gene fusions
83% of tech professionals would consider working in healthcare and pharma, with 72% more likely to consider it compared to six months ago, shows new research by Novartis
The multicentre programme will evaluate new tests in hospitals, GP surgeries and care homes around the country
The cannabinoid has been reclassified as a Schedule 5 medicine meaning that it can be dispensed more easily
New UK fund underpinned by £50 million investment from the British Business Bank, via its Enterprise Capital Funds (ECF) programme
The Association of Medical Research Charities and 151 of its members are calling on the UK government to match charity funded research for the next three years
The firms are working on the development of mRNA vaccines